Literature DB >> 16157085

A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women.

Laurence B McCullough1, John H Coverdale, Frank A Chervenak.   

Abstract

OBJECTIVE: We present and defend ethically justified guidelines for pharmacologic research that involves pregnant women. STUDY
DESIGN: We explain the ethical concept of the fetus as a patient and identify its ethical implications for the design and conduct of pharmacologic research that is intended to benefit pregnant women.
RESULTS: This concept justifies criteria for the initiation of early-phase clinical investigation, the initiation of controlled trials, the use of placebo control subjects, the stopping of randomized controlled trials, the determination of when an experimental intervention should be regarded as standard of care, and research that involves adolescents. The informed consent process should be shaped by the pregnant patient's obligation to take in to account her beneficence-based obligations to a fetal patient. Selection criteria should not be based on abortion preference. And, physicians are justified ethically in referring pregnant women to trials.
CONCLUSION: The concept of the fetus as a patient plays an essential role in the ethically justified design and conduct of pharmacologic research in pregnant women.

Entities:  

Mesh:

Year:  2005        PMID: 16157085     DOI: 10.1016/j.ajog.2005.06.020

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  14 in total

1.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Evidence-based medicine in obstetrics: can levels B and C recommendations be elevated to level A recommendations?

Authors:  Suneet P Chauhan; Eugene Chang; Brian Brost; Barbara Assel; Jason Baxter; James A Smith; Robert Grobman; Vincenzo Berghella; James A Scardo; Everett F Magann; John C Morrison
Journal:  Obstet Med       Date:  2009-05-22

3.  Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.

Authors:  Annemarie Unger; Reinhold Jagsch; Hendree Jones; Amelia Arria; Harald Leitich; Klaudia Rohrmeister; Constantin Aschauer; Berndadette Winklbaur; Andjela Bäwert; Gabriele Fischer
Journal:  Addiction       Date:  2011-05-12       Impact factor: 6.526

Review 4.  Management of breast cancer in pregnancy.

Authors:  Richard Theriault; Karin Hahn
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

5.  Enrolling pregnant women: issues in clinical research.

Authors:  Mary C Blehar; Catherine Spong; Christine Grady; Sara F Goldkind; Leyla Sahin; Janine A Clayton
Journal:  Womens Health Issues       Date:  2013-01

6.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

7.  A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics.

Authors:  S K Quinney; A N Mohamed; M F Hebert; D M Haas; S Clark; J G Umans; S N Caritis; L Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

Review 8.  The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics.

Authors:  J G Coen van Hasselt; Marilee A Andrew; Mary F Hebert; Joel Tarning; Paolo Vicini; Donald R Mattison
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

9.  Clinical therapeutics in pregnancy.

Authors:  Maisa N Feghali; Donald R Mattison
Journal:  J Biomed Biotechnol       Date:  2011-07-06

Review 10.  Bench-to-bedside review: human subjects research--are more standards needed?

Authors:  David T Huang; Mehrnaz Hadian
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.